Antisense oligonucleotides for mitogen-activated protein kinases as therapy for cancer

• US 6,007,991 A
• Filed: 08/12/1997
• Issued: 12/28/1999
• Est. Priority Date: 03/28/1997
• Status: Expired due to Fees

• Current Assignee: The Research Foundation of State University of New York
• Original Assignee: State University of New York
• Inventors: Malbon, Craig C., Sivaraman, Vimala S., Wang, Hsien-yu
• Primary Examiner(s): Degen, Nancy
• Assistant Examiner(s): WANG, ANDREW J
• Application Number:
  US08/909,742
• Time in Patent Office: 868 Days
• Field of Search: 514/44, 435/6, 435/91.1, 435/375, 435/325, 435/366, 536/24.5, 536/23.1
• US Class Current: 435/6.16
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C12N 15/1137 against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 2310/111 spanning the whole gene, or a large part of it
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/112 Disease subtyping, staging or classification

Abstract

A method is disclosed for inhibiting malignant neoplastic growth of epithelial or endothelial cells in a mammal by administering to the mammal an effective amount of an oligonucleotide complementary to at least a portion of mRNA for ERK-1 or ERK-2 that is overexpressed in the mammal. The antisense oligonucleotides are administered to the mammal as a dosage unit. A method of identifying and monitoring potentially malignant neoplastic cell growth in a mammal is also disclosed.

Claims

1. A method of inhibiting growth of malignant breast tumors in a mammal, which comprises injecting directly into the tumor an effective amount of an oligonucleotide having 10-100 nucleotides and complementary to the initiation codon of ERK-1 or ERK-2.

2. The method of claim 1, wherein said oligonucleotide is in an expression vector.

3. The method according to claim 1 wherein the oligonucleotide has 15-45 nucleotides.

4. The method according to claim 1 wherein the oligonucleotide has 15-32 nucleotides.

5. The method according to claim 1 wherein the oligonucleotide is selected from the group consisting of SEQ ID NO:

3 and SEQ ID NO;

4.